Multimodal Facility Design for Cell and Gene Therapies
Cell and gene therapies (CGTs) are progressing rapidly through development pipelines and advancing through clinical trial phases. Manufacturing capacity will need to be sufficient when such products are approved for commercialization. Thus, biomanufacturers are seeking ways to leverage multimodal facilities. Bioprocess International’s Maribel Rios spoke with Stephen Judd, principal process engineer for biologics and cell and gene therapy at DPS Group, about design considerations for multimodal facilities, how such facilities contribute to overall sustainability efforts, and the advantages brought on by different construction approaches.
You may be interested in
